Università di Pavia
- Address
- Viale Camillo Golgi 19, 27100 Pavia, Italy
Università di Pavia - AL Amyloidosis Research Center
The Università di Pavia is a distinguished academic medical institution with specialized expertise in rare systemic diseases, particularly focused on Light Chain (AL) Amyloidosis. The center demonstrates significant commitment to advancing therapeutic options for patients with advanced-stage amyloid disorders through participation in international multicenter clinical trials.
- Phase 3 therapeutic trials in Mayo Stage IV AL Amyloidosis patients
- Novel biologics evaluation including monoclonal antibody therapies combined with standard of care
- Long-term safety and efficacy assessment in life-threatening amyloid disease
The research center's involvement in randomized, double-blind, placebo-controlled studies targeting Mayo Stage IV subjects reflects their capability in managing complex patient populations with severe disease manifestations. Their participation in studies evaluating birtamimab and other emerging therapies positions them at the forefront of amyloidosis research, with particular emphasis on improving survival outcomes and establishing extended safety profiles for innovative treatment approaches in this challenging clinical domain.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Università di Pavia
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Birtamimab with Standard Care versus Placebo in Mayo Stage IV Light Chain Amyloidosis: A Phase 3 Randomized, Double-Blind Study | Prothena Biosciences Limited | Phase III | Not Recruiting | Oct 2021 | May 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Birtamimab | 1 | Unknown | 2021-10-13 | 2021-10-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.